Signs Exclusive License Agreement for Potentially Curative Gene Therapy Candidate for Diabetes

Genprex signed an exclusive license agreement with the University of Pittsburgh for a diabetes gene therapy that may have the potential to cure Type 1 and Type 2 diabetes, which together currently affect approximately 30.3 million people in the U.S.

Receives U.S. FDA Fast Track Designation for Gene Therapy that Targets Lung Cancer

Genprex was granted FDA Fast Track Designation for Oncoprex™ immunogene therapy in combination with EGFR inhibitor osimertinib for the treatment of non-small cell lung cancer (NSCLC) patients with EFGR mutations that progressed after treatment with osimertinib alone.

Reports Positive Preclinical Data for the Treatment of Some of the Most Resistant Metastatic Lung Cancers

Genprex’s TUSC2 gene therapy was found to increase the effectiveness of anti-PD1 immunotherapy and anti-PD1 immunotherapy combined with platinum chemotherapy in a humanized mouse model.

Independent researchers find TUSC2 prevents tumor growth in triple-negative breast cancer

Study finds that TUSC2 prevented tumor growth in triple-negative breast cancer, which is currently considered an incurable cancer with limited therapeutic options.

Provides forward looking guidance and updates on corporate activities, publishes new corporate deck

Announces anticipated milestones and future guidance on its clinical development programs, manufacturing and strategy for bringing its lead drug candidate, Oncoprex™ immunogene therapy, to market.

Demonstrates growth and expansion through recent achievements

Recent performance and achievements sets path for future milestones, commercialization.

Manufacturing partner completes significant step in manufacturing for Oncoprex™ clinical development program

Aldevron successfully completes the manufacturing of the TUSC2 (Tumor Suppressor Candidate 2) plasmid DNA that will be used in clinical trials evaluating Oncoprex™.

Begins next phase of drug branding program

Initiates the first phase of branding its lead drug candidate and completes the creation and submission of non-proprietary drug name selections to the USAN Council.

Addison Whitney is retained for drug nomenclature branding

Collaboration with Addison Whitney begins the drug naming development process and Genprex begins submission of non-proprietary name selections.

Positive preclinical data is published from the Oncoprex + pembrolizumab study

The study found that the combination of Oncoprex and the checkpoint inhibitor was more effective than checkpoint blockade alone in increasing the survival of humanized mice that had metastatic lung cancer. The combination treatment also slowed tumor growth significantly.

Strengthens senior team with two new hires

To advance operations, the company hires Eric Chapdelaine as Senior Director of Pharmaceutical Sciences and Manufacturing and Kalyn Dabbs as Senior Manager of Communications and Marketing.

Enters into exclusive agreement with UT MDACC for Oncoprex + immunotherapies study

The sponsored research agreement with the University of Texas MD Anderson Cancer Center is evaluating TUSC2 with immunotherapies, including immune checkpoint inhibitors, anti-PD1 and CTLA-4.

Key partners are selected to support acceleration of clinical development programs and manufacturing technology transfer

Genprex hires a consulting agency, an Institutional Review Board and Institutional Biosafety Committee, a Contract Research Organization and a commercial manufacturer to support the expansion of clinical development programs.

Genprex completes $10 Million Private Placement

Completes private placement raising $10 million of private stock.

Genprex begins trading under “GNPX” and expands operations

The company closes its IPO and begins trading under the ticker symbol “GNPX” on the Nasdaq Stock Market. Genprex also expands operations to Cambridge, Mass to accelerate the clinical development of Oncoprex.

Registration statement filed for proposed Initial Public Offering

The company prepares for its IPO with the Nasdaq Stock Market.

Positive preclinical data is published from the Oncoprex + immunotherapy study

The study reveals that Oncoprex, in combination with the anti-PD1 antibody, has significantly greater anti-tumor effect in lung cancer patients than either agent alone.

Positive interim data is published from the Phase II clinical trial evaluating Oncoprex + erlotinib

The study found that 4 of 9 patients had tumor regression within two cycles, and the trial’s disease control rate was 78%. One patient had a Complete Response.

Genprex expands its company management team and operations

The company appoints Julien Pham, MD, MPH as the company’s Chief Operating Officer and Ryan Confer, MS as Chief Financial Officer.

Preclinical studies evaluating Oncoprex + immunotherapies begin

Preclinical studies begin, evaluating Oncoprex in combination with immunotherapies, in mice with metastatic lung cancer.

Phase I/II clinical trial begins, evaluating Oncoprex + erlotinib

The Phase I portion of a I/II clinical trial is evaluating Oncoprex in combination with erlotinib in patients with Stage IIIB/IV metastatic lung cancer.

Phase I monotherapy clinical trial is published

The Phase I monotherapy trial found that for the first time, a tumor suppressor gene can be safely administered intravenously in lung cancer patients.

Genprex is founded

The company’s founders saw good potential in the science behind Genprex’s lead drug candidate, Oncoprex™ immunogene therapy, which has become the foundation of the company’s potentially life-changing technologies for cancer patients based on a unique proprietary technology platform.